Clinical Trials Logo

Clinical Trial Summary

Transthoracic ultrasonographic assessment of the diaphragmatic performance as a predictor for the outcome of NIV in critically ill COPD patients with acute exacerbation.


Clinical Trial Description

Chronic obstructive pulmonary disease (COPD) is considered a common disease worldwide, and it poses a major health and economic problem. COPD was the fifth leading cause for death in 2022 and will rank third by 2030. So, it's considered a devastating disease for patients and their loved ones . Patients presented with acute exacerbations of COPD may need respiratory intensive care unit (RICU) admission. Non invasive ventilation (NIV) is considered a cornerstone management option in patients with acute exacerbation of COPD (AECOPD). Therefore, early prediction of NIV failure may help in decision making regarding escalation to invasive mechanical ventilation To date, the diaphragm is the main respiratory muscle, and derangement of it's function is an important factor in the pathophysiology of COPD COPD patients have increased airway resistance and airflow limitation, which in turn increases the mechanical load of breathing exerted on the diaphragm Diaphragmatic weakness in COPD patients results from decreased muscle strength and mobility . Although, diaphragmatic performance is a key determinant of dyspnea in COPD patients, it is rarely assessed in clinical practice In practice, only vital sign such as respiratory rate and arterial blood gases parameters (ABG) such as PH, PaO2, PaCO2, SPO2, and fiO2/paO2 are considered predictors of NIV outcome. Assessment of diaphragmatic function transthoracic ultrasound (TUS) is a reliable, safe and bed side method for prediction of NIV outcome . Several tools commonly applied to determine diaphragmatic function such as; fluoroscopy, Computed tomography (CT), transdiaphragmatic pressure measurement, phrenic nerve stimulation, and electromyography can't be routinely used in intensive care units due to technical challenges and limitations ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06143150
Study type Observational
Source Assiut University
Contact Mona A. Mostafa, Master
Phone 01124629683
Email maiadel9995@gmail.com
Status Not yet recruiting
Phase
Start date November 15, 2023
Completion date December 15, 2027

See also
  Status Clinical Trial Phase
Recruiting NCT03440060 - Procalcitonin-guided Antibiotic Therapy During Severe Exacerbation of COPD N/A
Not yet recruiting NCT03277001 - Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD N/A
Terminated NCT03823443 - COPD Exacerbation Blood and Urine Biomarkers Study
Terminated NCT03079661 - Impact of Air Quality on Exacerbations of COPD in the Somme
Not yet recruiting NCT06123780 - Pattern of Microbial Infection in AECOPD Patients and Its Sensitivity to Antibiotics
Recruiting NCT03466385 - NHF vs NIV in Patients With Acute Exacerbation of COPD N/A